Nasus Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Dan Teleman
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.1yrs |
| CEO ownership | n/a |
| Management average tenure | 7.1yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO
Dan Teleman (53 yo)
Mr. Dan Teleman, MBA M.Sc., is the Chief Executive Officer at Nasus Pharma Ltd. since January 7, 2025 and serves as its Director since September 3, 2025. Mr. Teleman joined Nasus Pharma in January 2025.He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 7.1yrs | no data | 20.99% $ 13.8m | |
| CEO & Director | 1.1yrs | no data | no data | |
| Co-Founder | 7.1yrs | no data | 20.85% $ 13.7m | |
| CFO & Senior VP | less than a year | no data | no data | |
| Vice President of Administration & Human Resources | no data | no data | no data | |
| Director of CMC & Product Development | 7.1yrs | no data | 1.9% $ 1.2m |
Experienced Management: NSRX's management team is seasoned and experienced (7.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 7.1yrs | no data | 20.99% $ 13.8m | |
| CEO & Director | less than a year | no data | no data | |
| Co-Founder | 6.8yrs | no data | 20.85% $ 13.7m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 5.8yrs | no data | 0% $ 0 | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Advisory Board Member | no data | no data | no data | |
| Advisory Board Member | no data | no data | no data | |
| Advisory Board Member | no data | no data | no data | |
| Advisory Board Member | no data | no data | no data | |
| Advisory Board Member | 1.1yrs | no data | no data |
Experienced Board: NSRX's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/13 03:07 |
| End of Day Share Price | 2026/02/11 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nasus Pharma Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Butler | Citizens JMP Securities, LLC |
| I-Eh Jen | Laidlaw & Company (UK) Ltd |